Cefixime

Cefixime (FR-17027) is an orally active antibiotic and a third generation cephalosporin antibiotic, useful for the treatment of a number of bacterial infections[1][2].

79350-37-1

FR-17027; FK-027; CL-284635

12352005

H302, H315, H319, H335

Antibiotic; Bacterial

Reference compound

Anti-infection

COVID-19-immunoregulation

Infection; Cancer

https://www.medchemexpress.com/Cefixime.html

10mM

99.94

DMSO : 100 mg/mL (ultrasonic)

O=C(C1=C(C=C)CS[C@]([H])([C@@H]2NC(/C(C3=CSC(N)=N3)=N\OCC(O)=O)=O)N1C2=O)O

C16H15N5O7S2

453.45

H302, H315, H319, H335

[1]Neu HC, et al. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. Pediatr Infect Dis J. 1987 Oct;6 (10) :958-62.|[2]Unemo M, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012 Mar;56 (3) :1273-80.|[3]Matsumoto Y, et al. Antibacterial activity of cefixime against Salmonella typhi and applicability of Etest. J Infect Chemother. 1999 Sep;5 (3) :176-179. |[4]Connolly KL, et al. Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model. Antimicrob Agents Chemother. 2019 Feb 26;63 (3) :e01644-18.|[5]Shi Y, et al. Restoration of cefixime-induced gut microbiota changes by Lactobacillus cocktails and fructooligosaccharides in a mouse model. Microbiol Res. 2017 Jul;200:14-24.|[6]Stone JW, et al. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother. 1989 Feb;23 (2) :221-8.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

Reference compound1

Launched